Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
09:06am, Friday, 20'th Dec 2024
The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval.
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
07:24am, Friday, 20'th Dec 2024
On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.'s IONS Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, gen
TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease Indicated for adul
US FDA approves Ionis Pharma's genetic disorder drug
05:18pm, Thursday, 19'th Dec 2024
The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
10:55am, Wednesday, 11'th Dec 2024
The mean of analysts' price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 27'th Nov 2024
Ionis Pharmaceuticals (IONS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
10:37am, Monday, 18'th Nov 2024
Ionis Pharmaceuticals (IONS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
04:01pm, Thursday, 07'th Nov 2024
IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.
Ionis to present at upcoming investor conferences
07:05am, Thursday, 07'th Nov 2024
CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Gug
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
02:35pm, Wednesday, 06'th Nov 2024
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2024 Earnings Conference Call November 6, 2024 11:30 AM ET Company Participants Wade Walke – Senior Vice President of Investor Relations Brett Monia –
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
10:35am, Wednesday, 06'th Nov 2024
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wa
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
09:10am, Wednesday, 06'th Nov 2024
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.03 per share a year ago.
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
07:01am, Wednesday, 06'th Nov 2024
Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design Bayley-4 expressive communication selected as Phase 3 study primary endpoint Initiation of ION582 Phase 3 study plann
Ionis reports third quarter 2024 financial results
07:00am, Wednesday, 06'th Nov 2024
WAINUA TM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On tra
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
10:22am, Monday, 04'th Nov 2024
Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared
